Inhibiting "anchor" molecule in stem cells may improve marrow transplant process

Share this article:

The safety and efficiency of bone marrow transplants may improve due to the discovery of a rare molecule that establishes blood stem cells in their niche within the bone marrow.

The molecule—Robo4—is found only in the hematopoietic stem cells and in the endothelial cells of blood vessels. According to the new study findings, published in Cell Stem Cell (2011;8:72-83), hematopoietic stem cells—the key components in bone marrow transplants—use Robo4 to anchor themselves in the bone marrow where they reside.

In an increasingly common alternative to traditional bone marrow transplants, repeated drug injections are administered to usher stem cells away from bone marrow and into the bloodstream, from which they can be harvested and eventually groomed into different types of cells. The Robo4 discovery, however, creates an opportunity to find agents that can block the molecule in a safer and more effective fashion.

“If we can get specific and efficient inhibition of Robo4, we might be able to mobilize the hematopoietic stem cells to the blood more efficiently,” explained E. Camilla Forsberg, an assistant professor of biomolecular engineering at University of California–Santa Cruz, in a statement describing her team's work.

 

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Improved tyrosine kinase inhibitor (TKI) selectively activates in tumor tissue, minimizing side ...

A new strategy developed by an interdisciplinary team of researchers aims to reduce the side effects connected to use of tyrosine kinase inhibitors (TKIs).

Prior cancer exclusion criteria may stymie potential of lung cancer clinical trials

A history of prior cancer can exclude many individuals from participation in clinical trails related to lung cancer, even when the prior cancer is unlikely to interfere with treatment outcomes.

Better adherence to guidelines for safe handling of antineoplastic drugs is needed

Recommended safe handling practices for workers who administer antineoplastic drugs in health care settings are not always followed, according to a new study.